Anetumab ravtansine, an anti-mesothelin antibody conjugated to a tubulin inhibitor, is currently being evaluated in a variety of mesothelin-expressing tumors, including thymic carcinoma (NCT03102320; Figure 2) [71]. This evidence concerns the gene MSLN and thymic carcinoma.